Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

No one should have to choose between paying for prescription drugs and putting food on the table. That's why the Government of Canada is taking action so Canadians can get the medication they need, ...

The FDA has accepted the resubmission of a BLA for odronextamab for the treatment of patients with relapsed/refractory ...

On February 18, 2025, in United States v. Regeneron Pharmaceuticals, the First Circuit held that to establish civil liability under the False ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Actual terms vary by lender. The Mazda RX-8 price depends on several factors, including the trim level, optional features, mileage, vehicle history and location. The nationwide average price for ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Regeneron and Bayer have axed development of an ophthalmology combination therapy, saying it does not have sufficient potential to warrant late stage development. The companies were trialling the ...

Lexus has slimmed and simplified its usual derivative structure for this new RX. Buyers first choose from regular 350h hybrid, 450h+ plug-in hybrid and range-topping 500h hybrid powertrains ...

You may have done your research and settled on Wegovy for weight management or cardiovascular health. Now what? Telemedicine options might be your ticket to fulfill the prescription, deliver it ...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY ...

Regeneron will no longer seek accelerated approval for the bispecific antibody odronextamab in relapsed or refractory diffuse large B cell lymphoma, the pharma told Endpoints News on Wednesday.